Specturi Device - Feasibility Study
Specturi Device Study
On a daily basis many (prematurely born) newborn are subjected to different urine collecting techniques to study biochemical abnormalities. Neonatology nurses and pediatricians are looking for a better and less invasive manner to collect urine in these vulnerable patients. We hypothesise that the urine collecting device as presented in this protocol is less invasive and has good functional abilities to collect urine in these newborns
Objective of the study:
Clinical feasibility of the urine collection device, indicated by staff and parents.
Study design:
The study will be an open label, clinical feasibility study, of the urine collection device. During a period of 6 months, 30 feasibility tests will be performed.
Study population:
Prematurely born newborns, admitted to the neonatology unit of the department of pediatrics at Rijnstate Hospital Arnhem.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Bianca Baten
- Phone Number: +31(0)880056671
- Email: bbaten@rijnstate.nl
Study Contact Backup
- Name: Petra Van Setten
- Phone Number: +31 (0)24 361 1111
- Email: petra.vansetten@radboudumc.nl
Study Locations
-
-
Gelderland
-
Arnhem, Gelderland, Netherlands, 6800 TA
- Petra Van Setten
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Neonates admitted to the neonatology unit of the paediatrics department of Rijnstate Hospital Medical indication for urine testing for Calcium, Phosphate and Creatinine levels Informed consent from parents
Exclusion Criteria:
- No informed consent
- Defective skin in genital region
- Three previous tests in the same subject
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Questionnaire based clinical feasibility of the urine collection device, indicated by staff and parents
Time Frame: 1 day
|
With concern to feasibility we want to know whether this device is able:
|
1 day
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Skin reactions
Time Frame: 1 week
|
Number of times skin reactions occurs, reported by the responsible nurse
|
1 week
|
|
Skin irritability
Time Frame: 1 week
|
Number of times skin irritability occurs, reported by the responsible nurse
|
1 week
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NL55778.091.15
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rickets
-
NCT02720770CompletedX Linked Hypophosphatemic Rickets
-
NCT01652573CompletedHypophosphatemic Rickets, X Linked Dominant
-
NCT01237288CompletedPrimary Hypophosphatemic Rickets
-
NCT03233126CompletedX-linked Hypophosphatemic Rickets/Osteomalacia
-
NCT02181764CompletedX-linked Hypophosphatemic Rickets/Osteomalacia
-
NCT06248632Not yet recruitingX-Linked Hypophosphatemic Rickets
-
NCT07473973RecruitingAutosomal Recessive Hypophosphatemic Rickets | Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency | Generalized Arterial Calcification of Infancy 1
-
NCT02233322CompletedAutosomal Dominant Hypophosphatemic Rickets
-
NCT04308096Completed
-
NCT04372446CompletedGeneralized Arterial Calcification in Infancy | Autosomal Recessive Hypophosphatemic Rickets Type 2
Clinical Trials on Urinary collecting device
-
NCT02302183CompletedHypoxemic Acute Respiratory Distress | Infant Between 1 Month and 24 Months Old | Child Between 2 and 15 Years Old
-
NCT05275257WithdrawnUrinary Incontinence | Urinary Tract Infections | Cognition Disorders in Old Age | Incontinence-associated Dermatitis | Behavioral and Psychiatric Symptoms of Dementia
-
NCT05789849Recruiting
-
NCT04049019Completed
-
NCT03620604UnknownUrinary Incontinence,Stress
-
NCT01789229RecruitingEndocrine Gland Neoplasms | Breast Neoplasms | Lung Neoplasms | Colorectal Neoplasms | Ovarian Neoplasms | Neoplasms of the Female Genitalia
-
NCT07656701Not yet recruitingHealthcare Technology Adoption | Organizational Readiness
-
NCT07036978Not yet recruitingPancreatic Ductal Adenocarcinoma (PDAC)
-
NCT06831669RecruitingRectal Neoplasm Malignant
-
NCT05337501Active, not recruitingComplex Regional Pain Syndromes